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Thiazolidinediones (TZDs) improve insulin resistance
by activating a nuclear hormone receptor, peroxi-
some proliferator-activated receptor g (PPARg).
However, the use of TZDs is associated with plasma
volume expansion through a mechanism that re-
mains to be clarified. Here we showed that TZDs
rapidly stimulate sodium-coupled bicarbonate ab-
sorption from the renal proximal tubule in vitro and
in vivo. TZD-induced transport stimulation is depen-
dent on PPARg-Src-EGFR-ERK and observed in
rat, rabbit and human, but not in mouse proximal
tubules where Src-EGFR is constitutively activated.
The existence of PPARg-Src-dependent nonge-
nomic signaling, which requires the ligand-binding
ability, but not the transcriptional activity of PPARg,
is confirmed in mouse embryonic fibroblast cells.
The enhancement of the association betweenPPARg
and Src by TZDs supports an indispensable role of
Src in this signaling. These results suggest that the
PPARg-dependent nongenomic stimulation of renal
proximal transport is also involved in TZD-induced
volume expansion.
INTRODUCTION
Peroxisome proliferator-activated receptor g (PPARg) is
a ligand-activated transcription factor that belongs to the nuclear
hormone receptor gene superfamily (Yki-Ja¨rvinen, 2004). Phar-
macological activation of PPARg by thiazolidinediones (TZDs)
such as rosiglitazone (RGZ) and pioglitazone (PGZ) significantly
improves insulin resistance and lowers plasma glucose concen-
trations (Yki-Ja¨rvinen, 2004). TZDs may also have beneficial
effects on the cardiovascular system, including the reduction
of blood pressure and the improvement of vascular function550 Cell Metabolism 13, 550–561, May 4, 2011 ª2011 Elsevier Inc.(Ryan et al., 2004). However, fluid retention, one of the main
side effects of TZDs, precludes the use of TZDs in the setting
of severe heart failure (Mudaliar et al., 2003).
While the enhancement of sodium and fluid reabsorption from
the kidney, in addition to the peripheral vasodilatation, may
contribute to TZD-induced edema formation, the molecular
mechanism underlying the renal tubular actions of TZDs has
been a matter of controversy. Thus, the studies on mice with
the selective deletion of PPARg from renal collecting ducts orig-
inally suggested that TZD-induced volume expansion is depen-
dent on transport stimulation in the distal nephrons (Guan et al.,
2005; Zhang et al., 2005). In particular, the PPARg-mediated
enhanced transcription of the epithelial Na channel (ENaC) g
subunit was thought to play a key role (Guan et al., 2005; Zhang
et al., 2005). TZDs might also enhance the surface expression of
ENaC a subunit through the glucocorticoid-inducible kinase
SGK1 (Hong et al., 2003). However, other studies did not support
a central role of the ENaC in TZD-induced fluid retention. For
example, TZDs did not alter basal and insulin-stimulated ENaC
activities in well-established renal principal cell culture models
(Nofziger et al., 2005). In addition, TZDs did not consistently
enhance the expression of ENaC subunits (Song et al., 2004).
While an ENaC inhibitor, amiloride, prevented TZD-induced
volume expansion in mice (Guan et al., 2005), it failed to prevent
volume expansion in rats induced by a non-TZD PPARg agonist,
GI262570 (Chen et al., 2005). Furthermore, TZD-induced fluid
retention was not suppressed in mice lacking ENaC a subunit
selectively in collecting ducts (Vallon et al., 2009), strongly sug-
gesting that the enhancement of ENaC activity alone cannot
explain TZD-induced volume expansion. On the other hand,
both human (Zanchi et al., 2004) and animal (Muto et al., 2001)
studies suggested that renal proximal tubule (PT) transport could
be stimulated by TZDs. We reasoned that TZD-induced volume
expansion is multifactorial and that PTs may be another target
nephron segment of TZDs.
In the present study we demonstrate that TZDs markedly
stimulate in vitro and in vivo PT transport. This rapid transport
stimulation is dependent on PPARg-Src-EGFR-ERK and
observed in isolated PTs from rabbit, rat, and human. In mouse
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because of the unique constitutive activity of Src. The existence
of PPARg-Src-dependent nongenomic signaling, which requires
the ligand-binding ability, but not the transcriptional activity, of
PPARg is confirmed in mouse embryonic fibroblast (EF) cells.
Furthermore, TZDs rapidly enhance the association between
PPARg and Src, supporting an indispensable role of Src in this
signaling. We propose that, in addition to enhanced expression
of sodium transporter(s) through the PPARg-dependent
genomic signaling, the stimulation of renal PT transport through
the PPARg-dependent nongenomic signaling is also involved in
TZD-induced volume expansion.RESULTS
Effects of TZDs on Transport Functions in Isolated
Rabbit PTs
To examine whether TZDs can stimulate PT transport, we
first focused on the acute effects of TZDs on the electrogenic
Na+-HCO3
- cotransporter NBCe1 that mediates the majority of
Na+-coupled HCO3
- absorption from PTs (Li et al., 2008). In
isolated luminally collapsed rabbit PTs, 0.3 mM PGZ markedly
stimulated the NBCe1 activity within minutes (Figure 1A). Both
PGZ and RGZ stimulated the NBCe1 activity at submicromolar,
but not micromolar concentrations (Figures 1B and 1C). We next
examined the effects of TZDs on the activity of luminal Na+/H+
exchanger NHE3 in luminally perfused PTs and found that
0.3 mM PGZ markedly stimulated the NHE3 activity (Figures
S1A and S1B, available online). Submicromolar concentrations
of PGZ also enhanced the rate of HCO3
- absorption (JHCO3
-)
within 5 min (Figure 1D), indicating that TZDs can acutely stimu-
late the net Na+ and HCO3
- absorption from PTs by enhancing
the activities of both NBCe1 and NHE3.
To examine the signaling mechanism of TZD-induced stimula-
tion of PT transport, we used a tyrosine kinase inhibitor, genistein
(20 mM), a MEK inhibitor, PD98059 (10 mM), a PPARg antagonist,
GW9662 (5 mM), an EGFR tyrosine kinase inhibitor, AG1478
(20 mM), a PKC inhibitor, calphostin C (0.5 mM), and a PKA inhib-
itor, H89 (10 mM). All of these inhibitors did not change the basal
JHCO3
- values at the concentrations used in this study. While
genistein, PD98059, GW9662, and AG1478 largely suppressed
the PGZ-induced stimulation of JHCO3
-, calphostin C and
H89werewithout effects (Figure 1E). PGZ also rapidly stimulated
ERK phosphorylation in renal cortex tissues that was abolished
by AG1478, GW9662, and PD98059 (Figure 1F). These results
indicate that, among multiple rapid signaling pathways that are
potentially activated by TZDs (Burgermeister and Seger, 2008),
the EGFR/ERK pathway is critically involved in the effects of
TZDs on PT transport. To confirm the involvement of PPARg in
TZD-induced PT transport stimulation, we performed immuno-
histochemical analysis on rabbit kidneys. In addition to the
intense PPARg expression in inner medullary collecting ducts
as reported (Guan et al., 1997), the diffuse cytosolic expression
of PPARg in PTs was also evident (Figure 1G). Western blot anal-
ysis confirmed the expression of PPARg protein in both medulla
and cortex (Figure 1H). Together with the suppression of TZD-
induced PT transport stimulation by GW9662, these results
support a view that PPARg-dependent signaling is involved inCthe TZD-induced stimulation of PT transport. The specificity of
mouse and rabbit anti-PPARg antibodies is shown in Figure S1C.
Species Differences in TZD’s Effects on PT Transport
In view of potential species differences in the mechanism of
TZD-induced fluid retention (Chen et al., 2005; Guan et al.,
2005), we next examined the effects of TZDs on PT transport
in the different species. PGZ at 0.3 mM stimulated
NBCe1 activity in rats to a similar extent as in rabbits. However,
the stimulatory effect of PGZ was absent in mice (Figure 2A). In
mouse PTs, PGZ at concentrations from 0.003 to 3 mM failed
to stimulate JHCO3
- (Figure 2B). Because both rat and mouse
PTs express PPARg (Figures 2C and 2D), the lack of transport
stimulation by TZDs in mouse PTs cannot be attributable to the
absence of PPARg.
On the other hand, an Src inhibitor, PP2 (3 mM), completely
suppressed the stimulatory effect of PGZ on NBCe1 activity in
rabbit PTs (Figure 2E), consistent with the involvement of Src
in TZD-induced stimulation of PT transport. Interestingly, mouse
PTs were reported to have the unique constitutive activity of Src,
which was not found either in other mouse tissues or in PTs of
other species (Kiley and Chevalier, 2007). We hypothesized
that the constitutive activation of Src, together with the dysregu-
lation of downstreamEGFR signaling (Kiley andChevalier, 2007),
might be responsible for the lack of stimulatory effect of TZDs
in mouse PTs. Although PGZ stimulated renal cortex Src
phosphorylation in rabbits and rats, it failed to induce Src
phosphorylation in mice, presumably because of the highly
phosphorylated basal status (Figure 2F). PGZ also stimulated
ERK phosphorylation in rats, but not inmice because of the basal
activation (Figure 2G). These results suggest that the constitutive
activation of Src, which abolishes the estrogen receptor (ER)-
mediated nongenomic activation of endothelial NO synthase
(eNOS) (Li et al., 2007), also interferes with the PPARg-mediated
nongenomic signaling. In rat renal cortex, the PGZ-induced Src
phosphorylation was suppressed by PP2, but not by AG1478.
On the other hand, the PGZ-induced EGFR phosphorylation
was suppressed by both PP2 and AG1478 (Figure S2). These
results indicate that Src acts upstream of EGFR in the TZD-
induced signaling.
Notably, human PTs do not have the constitutive activation of
Src (Kiley and Chevalier, 2007) and hence may be sensitive to
the stimulatory effect of TZDs. Indeed, 0.3 mM PGZ markedly
stimulated the NBCe1 activity in isolated human PTs, and this
stimulation was totally suppressed by PD98059 and GW9662
(Figure 3A). Immunohistochemical analysis revealed that PPARg
was diffusely expressed in human PTs (Figure 3B). Furthermore,
western blot analysis confirmed the expression of PPARg
protein in isolated human PTs (Figure 3C).
Acute In Vivo Effects of TZDs
To examinewhether the TZD-induced stimulation of PT transport
modifies whole-body volume homeostasis, we performed acute
clearance studies in water-loaded conscious rats. Rats were
orally given PGZ at a single dose of 10 mg/kg body weight
(BW) and urine was collected for over 90 min. Taking account
of the high affinity of PGZ to plasma proteins, this protocol is esti-
mated to keep the protein-unbound, plasma PGZ concentration
at around 0.3 mM for at least 2 hr (Krieter et al., 1994). PGZell Metabolism 13, 550–561, May 4, 2011 ª2011 Elsevier Inc. 551
Figure 1. Stimulation of PT Transport by TZDs through PPARg-Dependent Pathway in Rabbits
(A) pHi responses to bath HCO3
- reduction from 25 to 12.5 mM (indicated as Low) in isolated rabbit PT.
(B) Concentration dependency of PGZ effects on NBCe1 activity. Open bars represent the control activities and closed bars represent the activities 5min after the
addition of PGZ. *p < 0.05 versus control; **p < 0.01 versus control. Data are means ± SEM. Each n = 7.
(C) Concentration dependency of RGZ effects on NBCe1 activity. **p < 0.01 versus control. Data are means ± SEM. Each n = 7.
(D) Concentration dependency of PGZ effects on the rate of JHCO3
-. Open bars represent the control fluxes and closed bars represent the fluxes 5 min after the
addition of PGZ. *p < 0.05 versus control; **p < 0.01 versus control. Data are means ± SEM. Each n = 7.
(E) Roles of protein kinases and PPARg in the stimulation of JHCO3
- by PGZ. Tubules were incubated with these inhibitors for 20 min. **p < 0.01 versus control.
Data are means ± SEM of six to eight experiments.
(F) ERK phosphorylation in rabbit renal cortex tissues. The sampleswere incubated for 40min in the absence or presence of inhibitors and 0.3 mMPGZwas added
for 5 min. Total ERK and P-ERK were detected.
(G) Immunohistochemical analysis of PPARg expression in rabbit kidney. The goat anti-PPARg antibody was applied in the absence or presence of antigen
(10 mg/L). Images are shown in pseudocolor, where green shows PPARg, red shows actin, and blue shows nuclei. Bars = 50 mm.
(H) Western blot analysis on rabbit kidney with the mouse anti-PPARg antibody. Each lane contained 20 mg of protein. See also Figure S1.
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Figure 2. Species Difference in Effects of TZDs on PT Transport
(A) Effects of 0.3 mM PGZ on NBCe1 activity in rabbit, rat, or mouse. **p < 0.01 versus control. Data are means ± SEM of seven to eight experiments. NS, not
significant.
(B) Concentration dependency of PGZ effects on JHCO3
- in mouse. Open bars represent the control fluxes and closed bars represent the fluxes 5 min after the
addition of PGZ. Data are means ± SEM. Each n = 6.
(C) Immunohistochemical analysis of PPARg expression in rat and mouse kidneys. Details are as in Figure 1G, but the rabbit anti-PPARg antibody was used.
Bars = 50 mm.
(D) Western blot analysis on rat and mouse kidneys with the rabbit anti-PPARg antibody. Each lane contained 20 mg of protein.
(E) Effects of 0.3 mM PGZ on NBCe1 activity in isolated rabbit PTs in the absence and presence of Src inhibitor PP2 (3 mM). Open bars represent the control
activities and closed bars represent the activities 5 min after the addition of PGZ. **p < 0.01 versus control. Data are means ± SEM. Each n = 7.
(F) Src phosphorylation in renal cortex tissues. The samples were treated with 0.3 mM PGZ for 5 min. Total Src, nonphosphorylated Src (NP-Src), and phos-
phorylated Src (P-Src) were detected.
(G) ERK phosphorylation in rat and mouse renal cortex tissues. Details are as in Figure 1F. See also Figure S2.
Cell Metabolism
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lithium (FELi+), and free water clearance (CH2O) without
changing creatinine clearance (CCr) or urinary sodium excretion
(UNaV) (Figure 4A). PGZ also slightly increased urinary osmolality
(Uosm), which could be explained by the stimulation of PT
absorption and the resultant decrease in delivery of water and
electrolytes to the loop of Henle (de Rouffignac et al., 1991).
Consistent with this interpretation, the simultaneous administra-Ction of a PT transport inhibitor, acetazolamide (ACZ), with PGZ
abolished the changes in UV, FELi+, CH2O, and Uosm. Systolic
blood pressure, analyzed by tail-cuff measurement, was unaf-
fected by PGZ (Figure S3A). Mild sodium depletion during the
acute clearance studies seemed to be responsible for the lack
of PGZ effect on UNaV. Indeed, PGZ significantly reduced UV,
FELi+, CH2O, as well as UNaV, and increased Uosm when rats
were loaded with half saline (0.45% NaCl) instead of waterell Metabolism 13, 550–561, May 4, 2011 ª2011 Elsevier Inc. 553
Figure 3. Effects of PGZ on Human PTs
(A) Effects of 0.3 mMPGZ on NBCe1 activity in isolated human PTs. Open bars
represent the control activities and closed bars represent the activities 5 min
after the addition of PGZ. **p < 0.01 versus control. Data are means ± SEM of
six to eight experiments.
(B) Immunohistochemical analysis of PPARg expression in human kidney.
Details are as in Figure 1G, but the rabbit anti-PPARg antibody was used.
Bars = 50 mm.
(C) Western blot analysis on human kidney with the rabbit anti-PPARg anti-
body. The left lane contained 30 PTs manually dissected from cortex slices
and the middle and right lanes each contained 20 mg of proteins.
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in vivo administration of PGZ enhanced ERK phosphorylation
in in situ PTs (Figure 4B), which was confirmed by western blot
analysis on renal cortex samples (Figure 4C). These results indi-
cate that TZDs can acutely induce fluid retention by stimulating
in vivo PT reabsorption in rats through the ERK-dependent
pathway. On the other hand, the chronic RGZ administration
for 3 days in rats was reported to enhance the expression of
collecting duct water channel protein AQP2 (Song et al., 2004).
However, we confirmed that the acute administration of PGZ
did not affect the expression of AQP2 in renal medulla
(Figure 4D).
We also performed acute clearance studies in mice with
the identical water-loading protocol (n = 11 for both control
and PGZ). Consistent with the lack of transport stimulation in
isolated mouse PT, the acute administration of PGZ did not
reduce UV (control, 3.8 ± 0.5 ml/10 g BW/min versus PGZ,
4.2 ± 0.4 ml/10 g BW/min), FELi+ (control, 19.1 ± 2.4% versus554 Cell Metabolism 13, 550–561, May 4, 2011 ª2011 Elsevier Inc.PGZ, 21.8 ± 4.0%) or CH2O (control, 0.62 ± 0.18 ml/10 g BW/min
versus PGZ, 0.80 ± 0.25 ml/10 g BW/min) in mice.
PPARg-Dependent Stimulation of NHE1 Activity
in EF Cells
To further examine the nature of the PPARg-dependent rapid
signaling pathway, we took advantage of EF cells, the only viable
cells available from PPARg/ mice (Kubota et al., 1999) and
focused on the regulation of NHE1, the ubiquitously expressed
Na+/H+ exchanger that is rapidly stimulated by the ERK pathway
(Haworth et al., 2003). The sustained intracellular acidosis stim-
ulated the NHE1 activity in both wild-type and PPARg/ cells
(Figure 5A). This stimulation was totally suppressed by
PD98059 (Figure 5B), indicating that the ERK-mediated
NHE1 stimulation is intact in both cell types. On the other
hand, 0.3 mM PGZ rapidly stimulated the NHE1 activity in wild-
type, but not in PPARg/ cells (Figure 5C). In wild-type cells,
PD98059, GW9662, and AG1478, but not a transcriptional inhib-
itor, actinomycin D, suppressed the PGZ-induced stimulation of
NHE1 activity (Figure 5D). Furthermore, GW9662 and
AG1478 suppressed the PGZ-induced ERK phosphorylation
that was detected only in wild-type cells (Figure 5E). RGZ at
0.3 mM also stimulated the NHE1 activity in wild-type cells by
79.9 ± 10.4% (p < 0.01, n = 8), but not in PPARg/ cells. These
results confirmed the existence of PPARg-dependent nonge-
nomic signaling resulting in ERK activation in wild-type EF cells.
They also support the previously proposed view that the consti-
tutive activation of Src/ERK pathway is restricted to mouse PTs
and is not found in other mouse tissues such as EF cells (Kiley
and Chevalier, 2007).
In contrast to the stimulatory effect of submicromolar concen-
trations of TZDs, 30 mM PGZ inhibited the NHE1 activity in both
wild-type (control, 0.048 ± 0.004 pH unit/min versus PGZ,
0.029 ± 0.002 pH unit/min, p < 0.01, n = 7) and PPARg/ cells
(control, 0.048 ± 0.004 pH unit/min versus PGZ, 0.028 ±
0.003 pH unit/min, p < 0.01, n = 7). RGZ at 30 mM also had
a similar inhibitory effect on the NHE1 activity in both wild-type
and PPARg/ cells (Figure S4). Consistent with a previous study
(Oliver et al., 2005), these results indicate that higher micromolar
concentrations of TZDs inhibit NHE1 independently of PPARg as
a class effect.
Nongenomic Nature of PPARg-Dependent Rapid
Signaling in EF Cells
To examine whether the NHE1 stimulatory activity of PPARg
can be discriminated from the gene transcriptional activity,
we performed adenovirus-mediated transfer of mouse
PPARg1 constructs (Figure 6A) into PPARg/ cells. As ex-
pected, the full-length PPARg was able to rescue the
NHE1 stimulation and ERK phosphorylation by 0.3 mM PGZ
(Figures 6B and 6C). More importantly, the ligand-binding
domain (LBD) construct, which lacks the entire N-terminal
transcription activation function domain AF-1 and the DNA-
binding domain, also rescued the NHE1 stimulation and ERK
phosphorylation by 0.3 mM PGZ (Figures 6D and 6E). However,
the binding-deficient LBD mutant Q284P, corresponding to
human Q286P (Sarraf et al., 1999), failed to rescue the
NHE1 stimulation or the ERK phosphorylation (Figures 6D and
6E). The failure of Q284P to rescue the PGZ-mediated
Figure 4. Effects of PGZ on In Vivo PT Transport
in Rats
(A) Acute renal clearance study. Urine was collected for
90min after a single oral dose of 10mg/kg PGZ or vehicle.
*p < 0.05 versus control; **p < 0.01 versus control. Data
are means ± SEM of 11–12 experiments. Each n = 7.
(B) Effects of PGZ on ERK phosphorylation in rat kidneys
in vivo. Sixty minutes after vehicle (Cont) or PGZ admin-
istration, kidneys were removed. Immunohistochemical
analysis was performed with the antiphospho-ERK anti-
body. Green shows phosphorylated ERK, red shows
actin, and blue shows nuclei. Bars = 50 mm.
(C) Western blot analysis on rat kidney cortex with the
anti-total ERK or the antiphosphorylated ERK antibody.
Sixty minutes after vehicle (Cont) or PGZ administration,
kidneys were removed. Each lane contained 20 mg of
proteins.
(D) Western blot analysis on rat kidney medulla with the
anti-AQP2 or the anti-actin antibody. Details are as in (C).
See also Figure S3.
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sion, because the full-lengthPPARg, LBD, andQ284Pshowedan
indistinguishable diffuse intracellular expression (Figure 6F).
These results indicate that the NHE1 stimulatory activity requires
the ligand-binding ability, but not the transcriptional activity, of
PPARg. We confirmed that a 5 min incubation with PGZ did not
change the pattern and level of intracellular PPARg expression.
To further confirm the dissociation of PPARg-mediated rapid
signaling from gene transcription, we examined adipocyte differ-
entiation, which absolutely requires the transcriptional activity of
PPARg (Kubota et al., 1999; Tontonoz et al., 1994). Themeasure-
ment of triglyceride (TG) contents revealed that wild-type, but
not PPARg/ cells had adipocyte differentiation ability (Fig-
ure S5). Whereas the full-length PPARg restored the ability of
PPARg/ cells to differentiate into adipocytes as reported
(Kubota et al., 1999), LBD or Q284P failed to restore adipocyte
differentiation (Figure S7). These results confirm that the
PPARg-mediated rapid signaling can be dissociated from the
gene transcriptional activity.
Roles of Src in PPARg-Dependent Rapid Signaling
in EF Cells
To examine the roles of Src in TZD-induced stimulation of
NHE1 activity, we next examined the effects of TZDs in EF cells
derived from Src/ mice (Klinghoffer et al., 1999). In Src+/+
control cells, but not in Src/ cells, 0.3 mM PGZ stimulated
the NHE1 activity (Figure 7A). The PGZ-induced ERK phosphor-Cell Metabolism 1ylation was also detected only in Src+/+ cells
(Figure 7B), though the definite expression of
PPARg was detected in both cell types (Fig-
ure 7C). These results confirm that Src is indis-
pensable in PPARg-dependent nongenomic
signaling.
In ER-mediated nongenomic signaling, the
association between ER and Src was thought
to play a key role (Li et al., 2007). Accordingly,
we finally examined a possible interaction
between PPARg and Src by coimmunoprecipi-tation assay. PPARg/ cells were transfected with PPARg, and
cell lysates were subjected to immunoprecipitation with anti-Src
or anti-PPARg antibodies. We found that Src and PPARg coim-
munoprecipitated each other and PGZ markedly enhanced this
association (Figures 7D and 7E). PGZ also markedly stimulated
the association between Src and LBD (Figure 7F). However,
PGZ failed to enhance the association between Src and
Q284P, indicating that the TZD-mediated recruitment of Src is
dependent on the ligand-binding ability of PPARg.
DISCUSSION
In the present study we showed that TZDs markedly stimulated
sodium-coupled bicarbonate absorption from isolated rabbit,
rat, and human PTs by activating both NBCe1 and
NHE3 through the PPARg/Src/EGFR/ERK pathway. Acute PGZ
administration in rats induced the stimulation of in vivo PT trans-
port. However, TZDs failed to stimulate in vitro and in vivo
PT transport in mice, in which Src-EGFR-ERK is uniquely
activated in a constitutive manner. Studies with EF cells
confirmed the presence of a nongenomic signaling pathway de-
pending on PPARg-Src-EGFR-ERK. Because the magnitude of
enhancement in PT transport by TZDs was actually comparable
to or even exceeded that by angiotensin II (Li et al., 2008),
a hormone with the greatest stimulatory effect in this segment,
we propose that the stimulation of renal PT transport through
PPARg-dependent nongenomic signaling is involved, at least3, 550–561, May 4, 2011 ª2011 Elsevier Inc. 555
Figure 5. Effects of PGZ on NHE1 Activity
in EF Cells
(A) The sustained intracellular acidosis induced by
3 mMHOE642 stimulated the NHE1 activity in both
wild-type (WT) and PPARg/ cells.
(B) The ERK-dependent activation of NHE1 by
sustained intracellular acidosis in EF cells. The
NHE1 activity was estimated by the rate of pHi
recovery at pHi of 6.9. Open bars represent
the control activities and hatched bars represent
the activities after intracellular acidosis.
**p < 0.01 versus control. Data are means ± SEM.
Each n = 6.
(C) Stimulation of NHE1 activity by 0.3 mM PGZ in
wild-type, but not in PPARg/ cells.
(D) Signaling mechanism underlying the stimula-
tion of NHE1 activity by PGZ. Actinomycin D
(ActD, 5 mM) was added to the medium for 1.5 hr
prior to pHi measurements. Open bars represent
the control activities and closed bars represent
the activities in the presence of 0.3 mM PGZ.
**p < 0.01 versus control. Data are means ± SEM
of six to seven experiments.
(E) ERK phosphorylation in EF cells. Cells
were incubated in the absence or presence of
inhibitors for 40 min and 0.3 mM PGZ was added
for 5 min. GW; GW9662. AG; AG1478. See also
Figure S4.
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Src-dependent Na/K pump activation by ouabain is dependent
on the NHE1 activation (Holthouser et al., 2010). It remains to
be determined whether the NHE1 activation plays a similar role
in the stimulation of PT transport by TZDs.
Although TZDs are known to trigger diverse rapid cellular
signaling events including the activation of kinase signaling path-
ways such as phosphatidylinositol 3-kinase (PI3K)/Akt, ERK,
EGFR transactivation, the production of reactive oxygen
species, or Ca2+ influx (Burgermeister and Seger, 2008), the
mechanisms underlying such dose-, time-, and cell type-depen-
dent responses have been largely unknown. The kinetics of
responses, the absolute requirement of ligand-binding ability,
and the nonrequirement of transcriptional activity shown in this
study clearly indicate that PPARg, like another nuclear receptor
ER (Kousteni et al., 2001), can activate the ERK pathway through
the nongenomic mechanism. The dependence on Src, the asso-
ciation between PPARg and Src, and the negative effect of
constitutive Src activation all support the central role of Src in
the PPARg-dependent nongenomic signaling. Src was previ-
ously shown to play a similar essential role in the ER-mediated
nongenomic signaling (Li et al., 2007). Subpopulations of ER
and/or a truncated variant of ER localized to specialized
membrane rafts caveolae are associated with several signaling
molecules, including Src and eNOS (Li et al., 2003). Interestingly,
PPARg is also associated with caveolin-1 (Burgermeister et al.,
2003), raising the possibility that a subset of PPARg, together
with other scaffold and signaling molecules including Src, may
form a membrane-localized signaling complex that is respon-
sible for the nongenomic actions. Also, it could be possible
that the direct association of PPARg and MEK (Burgermeister
and Seger, 2008) is involved in this signaling complex.556 Cell Metabolism 13, 550–561, May 4, 2011 ª2011 Elsevier Inc.In contrast to thePPARg-dependent stimulatory effects of sub-
micromolar concentrations of TZDs, suprapharmacological
concentrationsof TZDs inhibited theNHE1activity independently
of PPARg. Higher micromolar concentrations of TZDs were
known to induce other cellular responses including capacitive
calciumentry or rapid cellular acidosis, and such drastic changes
in cellular homeostasis could even result in PPARg-independent
ERK activation (Dewar et al., 2007; Friday et al., 2007). Thus,
caution is requiredwhen acute in vitro responses to highermicro-
molar concentrations of TZDs are to be analyzed in the absence
of ambient proteins. Notably, the protein-unbound peak plasma
concentrations of TZDs in human subjects are estimated to be
at submicromolar levels (Deng et al., 2005; Krieter et al., 1994),
well within the stimulatory range for PT transport.
Our study confirmed that important species differences exist
in the mechanism of TZD-induced fluid retention. The studies
on collecting duct-specific PPARg-deficient mice indicate
that the distal nephrons play a central role in TZD-induced
volume expansion in mice (Guan et al., 2005; Zhang et al.,
2005). While the role of ENaC is recently called into question,
TZDs may enhance the expression of other sodium and fluid
transporters through the classical genomic action of PPARg
(Vallon et al., 2009). The lack of TZD-induced transport stimula-
tion in mice PTs shown in the present study also supports the
central role of distal nephrons in TZD-induced volume expansion
in mice, though the actual transporter responsible for the
enhanced reabsorption in distal nephrons still remains to be
determined. On the other hand, several lines of evidence suggest
that the transport stimulation in distal nephrons alone cannot
explain TZD-induced volume expansion in species other than
mice. For example, amiloride failed to prevent the PPARg
agonist-induced volume expansion in rats (Chen et al., 2005).
Figure 6. Effects of Adenovirus-Mediated Transfer of PPARg Constructs into PPARg–/– Cells
(A) PPARg constructs. AF-1, transcription activation function domain; DNA, DNA-binding domain; ligand, ligand-binding domain; HA, hemagglutinin.
(B) Full-length PPARg rescued the PGZ-mediated stimulation of NHE1 activity. Open bars represent the control activities and closed bars represent the activities
in the presence of 0.3 mM PGZ. **p < 0.01 versus control. Data are means ± SEM of six to seven experiments.
(C) Full-length PPARg, but not LacZ, rescued the PGZ-mediated ERK phosphorylation.
(D) LBD, but not Q284P, rescued the PGZ-mediated stimulation of NHE1 activity. Open bars represent the control activities and closed bars represent the
activities in the presence of 0.3 mM PGZ. **p < 0.01 versus control. Data are means ± SEM of six to seven experiments.
(E) LBD, but not Q284P, rescued the PGZ-mediated ERK phosphorylation.
(F) Expression of endogenous PPARg or PPARg constructs in EF cells. Immunohistochemical analysis was performed by using the anti-PPARg antibody or the
anti-HA antibody. Green shows PPARg or LBD constructs, red shows actin, and blue shows nuclei. See also Figure S5.
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Thiazolidinedione-Induced Volume ExpansionIn addition, the chronic administration of TZDs in rats was re-
ported to enhance the renal abundance of a1 subunit of
Na+/K+ ATPase and the apical Na+/H+ exchanger NHE3 in PTs
(Song et al., 2004). TZDs were also found to enhance the expres-
sion of NHE3 through SGK1-mediated transcriptional activity of
PPARg in cultured human PT cells (Saad et al., 2009). These
changes in transporter abundance may further amplify the
TZD-induced nongenomic stimulation of PT transport in species
other than mice. Consistent with this view, the reduction in
lithium clearance was indeed reported in human subjects treatedCwith TZDs (Zanchi et al., 2004). Diuretics targeting the distal
nephrons were at least partially effective in preventing TZD-
induced mild volume expansion in human subjects with type
2 diabetes (Karalliedde et al., 2006). However, massive volume
expansion, the clinically more important side effect sometimes
observed in human subjects taking TZDs, is known to be resis-
tant to the conventional diuretic monotherapy (Mudaliar et al.,
2003). These considerations support a view that a mechanism
other than the stimulation of distal nephron transport is also
involved in TZD-induced fluid retention in humans.ell Metabolism 13, 550–561, May 4, 2011 ª2011 Elsevier Inc. 557
Figure 7. Roles of Src in TZD-Induced
Rapid Signaling in EF Cells
(A) Effects of PGZ on NHE1 activity in Src/ and
Src+/+ cells. Open bars represent the control
activities and closed bars represent the activities
in the presence of 0.3 mM PGZ. **p < 0.01 versus
control. Data are means ± SEM. Each n = 6.
(B) PGZ stimulated ERK phosphorylation in Src+/+
cells, but not in Src/ cells. PGZ (0.3 mM) was
added for 5 min.
(C) Western blot analysis was performed by using
the anti-PPARg antibody inSrc/ andSrc+/+ cells.
(D) Immunoprecipitation with the anti-PPARg
antibody in PPARg/ cells without or with
PPARg transfection.
(E) Immunoprecipitation with the anti-Src anti-
body in Src/ cells (left) or PPARg/ cells
transfected with PPARg (middle and right). PGZ
(0.3 mM) was added for 5 min.
(F) Immunoprecipitation with the anti-HA antibody
in PPARg/ cells transfected with LBD or
Q284P. PGZ (0.3 mM) was added for 5 min.
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Thiazolidinedione-Induced Volume ExpansionIn this context, it is noteworthy that the stimulation of sodium
transport in distal nephrons alone, induced by excessive aldo-
sterone actions, usually does not result in massive volume
expansion with edema formation, because a process known as
the ‘‘escape phenomenon’’ suppresses the sodium reabsorption
along PTs and other nephron segments (Gonzalez-Campoy
et al., 1989). On the other hand, the simultaneous stimulation
of sodium transport in PTs and distal nephrons through distinct
mechanisms is expected, at least under certain conditions, to
operate in a synergic manner. Massive volume expansion in
human subjects usually occurs after weeks of use of TZDs.
However, it can also occur as rapidly as 4 days after use of
TZDs (Hirsch et al., 1999), supporting the involvement of multiple
mechanisms. Thus, combination therapy with different diuretics
targeting bothPTs and thedistal nephrons could be a therapeutic
option in case of TZD-induced massive volume expansion.
Finally, this study represents an alternative paradigm in the
emerging concept that nuclear hormone receptors can mediate
nongenomic actions (Lo¨sel and Wehling, 2003). Different ligands
can bind to LBD of PPARg in slightly different ways and induce
different biological responses (Zhang et al., 2007). It could be
possible, therefore, to discriminate the diverse PPARg actions
at least partially by modifying the ligand-induced conformational
changes. Indeed, several selective PPARg modulators devel-
oped by such a concept are known to induce less fluid retention
at least in animals (Higgins andDepaoli, 2010). Future studies are
required to determine whether these selective PPARg modula-
tors can also prevent massive fluid retention in humans.
EXPERIMENTAL PROCEDURES
Measurements of NBCe1 and NHE3 Activities in Renal Proximal
Tubules
All animal procedures were in accordance with local institutional guidelines.
Japanese white rabbits, Wistar rats, or C57BL/6 mice were sacrificed with558 Cell Metabolism 13, 550–561, May 4, 2011 ª2011 Elsevier Inc.excessive amounts of pentobarbital and thin slices of kidney cortex were ob-
tained. For humanPTs, kidneycortex tissueswereobtainedduring theunilateral
nephrectomy for renal carcinoma. The institutional review board of University of
Tokyo School of Medicine approved the study and written informed consent
wasobtained fromall thesubjects. ThePT (S2segment) fragmentwasmicrodis-
sectedmanuallyand transferred toaperfusionchambermountedonan inverted
microscope. For the analysis of NBCe1 activity, the luminally collapsed tubule
was used as described (Li et al., 2008). The tubule was incubated with an
acetoxymethyl ester form of a pH-sensitive fluorescence dye 20,70-bis(carbox-
yethyl)-5(6)-carboxyfluorescein (BCECF/AM; Dojindo) and pHi was monitored
with a photometry system (OSP-10; Olympus). Calibration curves for pHi were
obtained according to themethod described (Thomas et al., 1979). Prewarmed
(38C)Dulbecco’smodifiedEagle’smedium (DMEM)equilibratedwith5%CO2/
95% O2 gas was used for the peritubular perfusate, which was shown to be
essential for the long-term functional preservationof isolatedPTs (Mu¨ller-Berger
et al., 1997;Zheng et al., 2003) The rate of pHi decrease to bathHCO3
- reduction
and the buffer capacity were used to calculate the NBCe1 activity as described
(Li et al., 2008). For the analysis of NHE3 activity, pHi was monitored in the
microperfused S2 segment as described (Yamada et al., 1996). Initially, both
luminal and bath sides were perfused with HEPES-buffered Ringer solution
equilibrated with 100% O2 and thereafter, luminal perfusate was switched to
Na+-free HEPES solution that replaces Na+ in HEPES-buffered Ringer solution
with N-methyl-D-glucamine. The resultant decrease in pHi was shown to reflect
the luminal NHE3 activity (Yamada et al., 1996).
Determination of Bicarbonate Absorption Rates
Weused the stop-flowmicrospectrofluorometricmethod as described (Mu¨ller-
Berger et al., 1999; Zheng et al., 2003). Isolated PTs were microperfused and
luminal pH (pHL) was monitored on the OSP-10 system. The tubular lumen
wasperfusedwithRinger solution, which contained 25mMHCO3
-, 40mMraffi-
nose, and 40 mM BCECF, and DMEM was used for the bath perfusate. To
determine JHCO3
-, we abruptly stopped the rapid (80 nl/min) luminal perfu-
sion by suddenly reducing the perfusion pressure from 18 to 0 cm H2O. The
decay in luminal HCO3
- concentration was calculated from the changes in
pHL and JHCO3
- was calculated as described (Mu¨ller-Berger et al., 1999).
Renal Clearance Protocol
Adult female Wistar rats weighing between 140 and 170 g were used. The rats
were individually housed in metabolic cages. Three days before study, the diet
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Thiazolidinedione-Induced Volume Expansionwas changed from a standard diet to one containing lithium chloride (6 mM/kg
dry weight) to yield measurable plasma lithium concentrations without
affecting renal function (Shalmi and Thomsen, 1989). On the morning of clear-
ance study water and food were withdrawn andmaximal diuresis was induced
by water loading to facilitate the detection of rapid alterations in PT transport.
Each rat received a load of tap water by gavage (5% of the body weight),
followed by a second load of the same volume with PGZ (n = 12) or vehicle
(citric acid, n = 12) 4 hr later. Thirty minutes after the second load, spontane-
ously voided urine was collected over 90 min. In the ACZ group, ACZ
(100 mg/kg BW) was given orally with PGZ (n = 11) or the vehicle (n = 12). At
the end of the experiment, blood samples were drawn through cardiac
puncture in anesthetized rats. Serum and urine data were measured by the
SRL clinical service. Renal clearance (C) was calculated by a standard formula
(C = UV/P) and CH2O was calculated by the following formula: CH2O =
(1  Uosm/Posm) 3 UV, where Uosm and Posm denote osmolality of urine
and plasma, respectively. FELi+ was calculated as CLi+/CCr. The blood pres-
sure of restrained conscious rats was measured by a programmed tail-cuff
sphygmomanometer (BP-98A; Softron).
Measurement of NHE1 Activity
EF cells from wild-type and PPARg/ mice were harvested from 13.5 dpc
embryos and were maintained in DMEM supplemented with 10% fetal bovine
serum (FBS) as described (Klinghoffer et al., 1999). EF cells derived from
mouse embryos deficient in c-Src, Yes, and Fyn (Src/) or from embryos
lacking both Yes and Fyn, but maintaining normal levels of c-Src (Src+/+),
were obtained from American Type Culture Collection. When cells reached
confluency, they were trypsinized and seeded onto 6 mm round coverslips.
Cell-coated coverslips were incubated with HEPES-buffered Ringer solution
containing BCECF/AM for 30–60 min at room temperature. The coverslip
was then superfused with prewarmed (38C) experimental solutions at
5 ml/min. The NHE1 activity was determined as described (Haworth et al.,
2003). Briefly, the HEPES solution was changed to another solution containing
20 mM NH4Cl (instead of the equimolar NaCl) for several minutes. The reintro-
duction of the HEPES solution typically induced pHi to decrease to a level
around pH 6.7 and thereafter, pHi started to recover from intracellular acidosis.
This pHi recovery reflects the NHE1 activity, because it was almost completely
inhibited by 3 mM HOE642 (Sanofi Aventis), a specific inhibitor of NHE1. The
NHE1 activity was estimated by calculating the rate of pHi recovery at fixed
pHi of 6.9 during the recovery from intracellular acidosis.
Adenovirus-Mediated Gene Transfer
The full-length mouse PPARg1 expression vector for adenovirus-mediated
gene transfer was constructed by using AdEasy Vector system (Promega)
and pCMX-PPARg1 (kindly provided by Dr. B. M. Spiegelman) according to
the manufacturer’s instructions. In addition, the hemagglutinin (HA)-tagged
LBD of PPARg, corresponding to amino acids 184–475, and the LBD contain-
ing Q284P mutation, which is devoid of the binding affinity for TZDs (Sarraf
et al., 1999), were constructed by PCR-based site-directed mutagenesis
(Stratagene) and confirmed by DNA sequencing. These constructs were also
subcloned into the adenovirus vector. The EF cells were infected with each
recombinant virus at a multiplicity of infection of 220 plaque-forming units/
cell, and 48 hr later pHi measurement was performed.
Antibodies
The anti-PPARg antibodies were from Santa Cruz Biotechnology, the rabbit
anti-HA was from Bethyl Laboratories, and the rabbit and mouse anti-Src
were from Cell Signaling Technology. Antibodies against total ERK, phos-
pho-ERK (P-ERK), nonphospho-Src (NP-Src), and phospho-Src (P-Src,
tyrosine-416) were from Cell Signaling Technology. The horseradish peroxi-
dase (HRP)-conjugated anti-rabbit or anti-mouse IgG were from Jackson
ImmunoResearch Laboratories. Alexa Fluor 488 anti-rabbit IgG and Alexa
Fluor 568 phalloidin were fromMolecular Probes and 40,6-diamidino-2-phenyl-
indole dihydrochloride (DAPI) was from Boehringer Mannheim.
Immunoblotting and Immunoprecipitation
For detection of PPARg, kidney tissues or cell samples were homogenized
in ice-cold buffer containing 280 mmol/L sucrose and complete protease
inhibitor cocktail (Roche). For detection of PPARg in PTs, human PTs ofC1 mm length were manually dissected from thin kidney slices and were
homogenized in the same buffer. For detection of phosphorylation of ERK or
Src, thin slices of kidney cortex were obtained. They were divided into pieces
of small bundles consisting mostly of PTs as described (Li et al., 2008). These
samples were incubated at 37C for 40 min in DMEM under 5% CO2 in the
absence or presence of several inhibitors. After TZDs were added for the indi-
cated time, samples were homogenized in ice-cold lysis buffer containing
25 mM Tris-HCl (pH 7.4), 10 mM sodium orthovanadate, 10 mM sodium pyro-
phosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM EGTA, and 1 mM
phenylmethylsulfonyl fluoride. For detection of in vivo ERK phosphorylation,
rats were sacrificed with excessive amounts of pentobarbital and kidney
cortex samples were immediately homogenized in the lysis buffer. Equal
amounts of protein samples were obtained from the supernatants, separated
by SDS-PAGE on 7% acrylamide minigels, and transferred to a nitrocellulose
membrane. After incubation in blocking buffer, themembrane was treatedwith
one of the primary antibodies and then with their respective secondary anti-
bodies. The signal was detected by an ECL Plus system (Amersham).
EF cells were grown on a 10 cm culture dish and FBS was removed over-
night. Thereafter, cells were incubated for 40min in the absence and presence
of several inhibitors. After TZDs were added for the indicated time, cells were
collected, lysed with the lysis buffer, and subjected to immunoblotting. For
immunoprecipitation with PPARg or Src, the cell lysate was precleaned by
incubation with Protein G Sepharose 4 Fast Flow (GE Healthcare Bio-Science)
and incubated with the mouse anti-PPARg or the mouse anti-Src antibodies
coupled to Protein G Sepharose 4 Fast Flow. The immunoprecipitates were
washed three to five times with the lysis buffer containing 1% Nonidet
P-40 and subjected to immunoblotting with the rabbit anti-PPARg or the rabbit
anti-Src antibody. For immunoprecipitation with HA, the rabbit anti-HA
antibody was coupled to Protein A Sepharose 4 Fast Flow (GE Healthcare
Bio-Science) and immunoblotting was performed with the rabbit anti-HA or
the rabbit anti-Src antibody.
Immunohistochemical Analysis
To examine the intrarenal expression of PPARg, we fixed the kidney samples
from humans and rabbits with buffered 4% paraformaldehyde (PFA),
sectioned them 5 mm thick in the cryostat at 25C, air-dried them, and
immersed them in PBS, which was followed by incubation with anti-PPARg
(1:100 dilution) overnight at 4C. The specimens were subsequently incubated
with the mixtures of Alexa Fluor 488 anti-rabbit or anti-goat IgG, Alexa Fluor
568 phalloidin for labeling of F-actin, and DAPI for labeling of nuclei for
60 min at room temperature. The kidneys from rats and mice were frozen
without fixation and cryosectioned at 10 mm thick and then fixed with buffered
4% PFA for 10 min. After being washed with PBS, sections were serially incu-
bated with anti-PPARg (1:50) for 1 hr and the mixtures of Cy5-conjugated anti-
rabbit IgG, Alexa Fluor 568 phalloidin, and SYBRGreen I for nuclei for 30min at
room temperature. An absorption test was performed in the presence of
antigen peptide (10mg/L). The specimens were observedwith a confocal laser
scanning microscope (MRC-1024K; Japan Bio-Rad Laboratories or
LSM510META, Carl Zeiss). For the determination of intrarenal ERK phosphor-
ylation, the antiphospho-ERK and Alexa Fluor 488 anti-rabbit IgG were used.
To examine the expression of endogenous PPARg or exogenous PPARg
constructs in EF cells, we fixed the cells with buffered 4% PFA and processed
them for immunostaining as described above by using the anti-PPARg anti-
body or the anti-HA antibody as the primary antibody.
Adipocyte Differentiation
EF cells were plated on six-well plastic dishes and propagated to confluence.
Two days later, medium was replaced with standard differentiation medium
containing 0.5 mM 3-isobutyl-1-methylxanthine, 10 mM dexamethasone,
0.86 mM insulin, 0.3 mMPGZ, and 10%FBS. After 8 days, cells were harvested.
The TG levels in the cell lysates were quantified by using the Triglyceride
E-test Wako kit (Wako Pure Chemical) according to the manufacturer’s
protocol.
Statistical Analysis
Data are means ± SEM. Significant differences were determined by applying
Student’s t test or ANOVA with Bonferroni’s adjustment as appropriate.
Statistical significance was set at p < 0.05.ell Metabolism 13, 550–561, May 4, 2011 ª2011 Elsevier Inc. 559
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